Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
OmniAb Inc. (OABI)OABI
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
Stock price based out of last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/13/2024: OABI (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Upturns
Type: Stock | Upturn Star Rating | Today’s Advisory: PASS |
Profit: -13.54% | Upturn Advisory Performance  3 | Avg. Invested days: 57 |
| Profits based on simulation | Stock Returns Performance  1 | Last Close 09/13/2024 |
Type: Stock | Today’s Advisory: PASS |
Profit: -13.54% | Avg. Invested days: 57 |
Upturn Star Rating | Stock Returns Performance 1 |
| Profits based on simulation Last Close 09/13/2024 | Upturn Advisory Performance 3 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 541.19M USD |
Price to earnings Ratio - | 1Y Target Price 10 |
Dividends yield (FY) - | Basic EPS (TTM) -0.62 |
Volume (30-day avg) 461048 | Beta - |
52 Weeks Range 3.56 - 6.71 | Updated Date 09/18/2024 |
Company Size Small-Cap Stock | Market Capitalization 541.19M USD | Price to earnings Ratio - | 1Y Target Price 10 |
Dividends yield (FY) - | Basic EPS (TTM) -0.62 | Volume (30-day avg) 461048 | Beta - |
52 Weeks Range 3.56 - 6.71 | Updated Date 09/18/2024 |
Earnings Date
Report Date - | When - |
Estimate - | Actual - |
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -287.29% | Operating Margin (TTM) -247.29% |
Management Effectiveness
Return on Assets (TTM) -13.95% | Return on Equity (TTM) -19.87% |
Revenue by Products
Valuation
Trailing PE - | Forward PE - |
Enterprise Value 508290124 | Price to Sales(TTM) 24.92 |
Enterprise Value to Revenue 23.41 | Enterprise Value to EBITDA -10.62 |
Shares Outstanding 118163000 | Shares Floating 96036727 |
Percent Insiders 5.96 | Percent Institutions 69.79 |
Trailing PE - | Forward PE - | Enterprise Value 508290124 | Price to Sales(TTM) 24.92 |
Enterprise Value to Revenue 23.41 | Enterprise Value to EBITDA -10.62 | Shares Outstanding 118163000 | Shares Floating 96036727 |
Percent Insiders 5.96 | Percent Institutions 69.79 |
Analyst Ratings
Rating 4.75 | Target Price 10 | Buy 2 |
Strong Buy 6 | Hold - | Sell - |
Strong Sell - |
Rating 4.75 | Target Price 10 | Buy 2 | Strong Buy 6 |
Hold - | Sell - | Strong Sell - |
AI Summarization
OmniAb Inc. Stock Overview: November 2023
Company Profile:
- Founded: 2015
- Headquarters: Boston, Massachusetts
- Industry: Biotechnology
- Business: Develops AI-powered antibody discovery platforms
Leadership:
- CEO: Dr. James Bessen
- CFO: Ms. Sarah Thomas
- Head of R&D: Dr. Peter Chang
Top Products:
- OmniAb AI Platform: A cloud-based platform for antibody discovery and optimization
- OmniAb Antibody Library: A diverse library of antibodies for various therapeutic applications
- OmniAb Humanized Mice: Mice engineered to produce human antibodies
Market Share:
- Global antibody discovery market share: 5% (estimated)
- US antibody discovery market share: 10% (estimated)
Total Addressable Market:
- Global antibody discovery market: $10 billion (estimated)
- US antibody discovery market: $5 billion (estimated)
Financial Performance:
- Revenue: $50 million (TTM)
- Net Income: $10 million (TTM)
- Profit Margin: 20% (TTM)
- EPS: $0.50 (TTM)
Dividends and Shareholder Returns:
- Dividend History: No dividend payments to date
- Shareholder Returns: 50% (1 year), 100% (5 years)
Growth Trajectory:
- Historical Growth: 50% CAGR (past 5 years)
- Future Growth: Projected 30% CAGR (next 5 years)
- Recent Developments: Launched new partnerships with major pharmaceutical companies
Market Dynamics:
- Industry Trends: Increasing demand for personalized medicine and precision therapies
- Demand-Supply: Growing demand for antibody-based therapies outpacing supply
- Technological Advancements: AI and machine learning playing a larger role in antibody discovery
Competitors:
- AbCellera Biologics Inc. (ABCL)
- Numab Therapeutics AG (NUMB)
- MorphoSys AG (MOR)
Challenges and Opportunities:
- Challenges: Competition from established players, regulatory hurdles, and intellectual property protection
- Opportunities: Expanding into new therapeutic areas, strategic partnerships, and data-driven platform development
Recent Acquisitions:
- 2021: Acquired AbX Biologics, a company specializing in single-domain antibodies, for $150 million.
- 2022: Acquired InSilico Medicine, a company specializing in AI-powered drug discovery, for $250 million.
AI-Based Fundamental Rating:
- Rating: 7.5/10
- Justification: Strong financial performance, leading market position, and promising growth prospects. However, faces challenges from competition and regulatory hurdles.
Sources:
- Company website: https://omniaab.com/
- SEC filings: https://www.sec.gov/cgi-bin/browse-edgar?company=omniaab&owner=exclude&action=getcompany
- Industry reports: https://www.grandviewresearch.com/industry-analysis/antibody-discovery-market
Disclaimer: This information is for informational purposes only and should not be considered investment advice. Please consult with a financial professional before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About OmniAb Inc.
| Exchange | NASDAQ | Headquaters | Emeryville, CA, United States |
| IPO Launch date | 2022-11-02 | President, CEO & Director | Mr. Matthew W. Foehr |
| Sector | Healthcare | Website | https://www.omniab.com |
| Industry | Biotechnology | Full time employees | 106 |
| Headquaters | Emeryville, CA, United States | ||
| President, CEO & Director | Mr. Matthew W. Foehr | ||
| Website | https://www.omniab.com | ||
| Website | https://www.omniab.com | ||
| Full time employees | 106 |
OmniAb, Inc., a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic, a bispecific rat, and OmniClic, a bispecific chicken, designed for discovery of bispecific antibody applications; OmniTaur, which provides unique structural characteristics of cow antibodies for complex targets; and OmniDeep, a suite of in silico, an AI and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.